These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9124868)

  • 1. Different effects of zinc ions on in vitro susceptibilities of Stenotrophomonas maltophilia to imipenem and meropenem.
    Cooke P; Heritage J; Kerr K; Hawkey PM; Newton KE
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2909-10. PubMed ID: 9124868
    [No Abstract]   [Full Text] [Related]  

  • 2. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
    García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García Sánchez E; García García MI
    J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.
    Howe RA; Wilson MP; Walsh TR; Millar MR
    J Antimicrob Chemother; 1997 Jul; 40(1):13-7. PubMed ID: 9249199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.
    Piddock LJ; Turner HL
    Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1186-91. PubMed ID: 1291320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions.
    Hawkey PM; Birkenhead D; Kerr KG; Newton KE; Hyde WA
    J Antimicrob Chemother; 1993 Jan; 31(1):47-55. PubMed ID: 8444674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal susceptibility to meropenem.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1996 May; 37(5):1036-7. PubMed ID: 8737158
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibiotic susceptibilities of the Vibrionaceae to meropenem and other antimicrobial agents.
    Clark RB
    Diagn Microbiol Infect Dis; 1992 Jul; 15(5):453-5. PubMed ID: 1643823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).
    Visser MR; Hoepelman IM; Beumer H; Rozenberg-Arska M; Verhoef J
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1061-4. PubMed ID: 2695328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.
    Hoban DJ; Jones RN; Yamane N; Frei R; Trilla A; Pignatari AC
    Diagn Microbiol Infect Dis; 1993; 17(4):299-305. PubMed ID: 8112045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem.
    Pragai Z; Nagy E
    J Antimicrob Chemother; 1998 Dec; 42(6):821-4. PubMed ID: 10052909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.
    Giacometti A; Siquini FM; Cirioni O; Petroni S; Scalise G
    Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):315-8. PubMed ID: 8070438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outer membrane permeability of Serratia marcescens to meropenem and imipenem.
    Raimondi A; Pessina A; Cocuzza G
    J Chemother; 1994 Dec; 6(6):363-7. PubMed ID: 7699421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the in vitro postantibiotic effect of meropenem and imipenem versus selected enterobacteriaceae and other pathogens.
    Nadler HL; Sheikh W
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):71-3. PubMed ID: 8359011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
    Lang C; Beuth J; Ko HL; Tunggal L; Pulverer G
    Zentralbl Bakteriol; 1992 Dec; 277(4):485-92. PubMed ID: 1303691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactamase stability and inhibitory activity of meropenem combined with a potent antibacterial activity.
    Nouda H; Harabe ET; Sumita Y; Okuda T; Fukasawa M
    Chemotherapy; 1992; 38(4):218-24. PubMed ID: 1473360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.
    Kocazeybek BS; Arabaci U
    Int J Antimicrob Agents; 2002 Feb; 19(2):159-62. PubMed ID: 11850170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.